Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of GEn-1124 in Healthy Subjects
NCT07185113Phase 1Completed
- Sponsor
- GEn1E Lifesciences
- Start
- Oct 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GEN-1124, sponsored by GEn1E Lifesciences. Primary endpoints: Pharmacokinetics (Plasma levels of GEn-1124), Clinically significant changes to physical exam and 4 more. Started Oct 2025; status: completed.
02
Drugs
GEN-1124
Beyond the preview
Go deeper on NCT07185113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185113.